18 September 2020 (Friday) - ASH Update

The American Society of Hematology sent an update today. Probably more along the lines of “background reading” than directly relevant to me, but an update on myeloma is always useful.



EHA25 Virtual: Phase I Trial Supports CC-92480 for Heavily Pretreated Myeloma
Results from a first-in-human trial of CC-92480 plus dexamethasone in patients with relapsed/refractory myeloma show a manageable safety profile and promising efficacy.


Belantamab Mafodotin-blmf Approved for Relapsed/Refractory Multiple Myeloma
Approval was based on results from DREAMM-2, in which treatment with belantamab mafodotin-blmf 2.5 mg/kg every 3 weeks led to a clinically meaningful response in 31% of patients.


EHA25 Virtual: Idecabtagene Vicleucel Demonstrates Deep, Durable Responses in Relapsed/Refractory Myeloma
The BCMA-targeted CAR T-cell therapy induced responses in nearly 75% of patients with triple-class-exposed myeloma.

No comments:

Post a comment